Immunic, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Immunic, Inc. (IMUX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.42M, a 185.20% increase year-over-year.
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.44M, a 29.33% decline year-over-year.
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.11M, a 10.47% increase year-over-year.
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.90M, a 0.90% increase year-over-year.
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.05M, a 5.55% decline from fiscal 2024.
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.53M, a 20.06% increase from fiscal 2023.
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.10M, a 10.43% decline from fiscal 2022.
- Immunic, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $7.93M, a 33.28% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.42M 10-Q · filed 2026-08-11 | $6.86M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $1.44M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $8.05M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $2.11M 10-Q · filed 2025-11-13 | $4.01M derived: sum of 2 quarters · filed 2026-08-11 | $6.05M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.90M 10-Q · filed 2026-08-11 | $3.94M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.04M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $8.53M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $1.91M 10-Q · filed 2025-11-13 | $3.79M derived: sum of 2 quarters · filed 2025-11-13 | $6.54M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.88M 10-Q · filed 2025-11-13 | $4.63M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $2.75M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $7.10M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $1.69M 10-Q · filed 2024-11-07 | $3.48M derived: sum of 2 quarters · filed 2024-11-07 | $5.46M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $1.80M 10-Q · filed 2024-11-07 | $3.78M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $1.98M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $7.93M 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $1.91M 10-Q · filed 2023-11-14 | $3.97M derived: sum of 2 quarters · filed 2023-11-14 | $6.04M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $2.06M 10-Q · filed 2023-11-14 | $4.13M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $2.07M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $5.95M 10-K · filed 2023-02-23 | |||
| 2021-09-30 | $1.40M 10-Q · filed 2022-11-03 | $2.90M derived: sum of 2 quarters · filed 2022-11-03 | $4.48M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $1.51M 10-Q · filed 2022-11-03 | $3.09M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $1.58M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $2.75M 10-K · filed 2022-02-24 | |||
| 2020-09-30 | $707.00K 10-Q · filed 2021-11-04 | $1.08M derived: sum of 2 quarters · filed 2021-11-04 | $1.43M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $369.00K 10-Q · filed 2021-11-04 | $722.00K derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $353.00K 10-Q · filed 2021-11-04 | |||
| 2019-09-30 | $199.00K 10-Q · filed 2020-11-06 | $199.00K 10-Q · filed 2019-11-07 | ||
| 2019-03-31 | $6.10M 10-Q · filed 2019-04-10 | |||
| 2018-12-31 | $3.74M 10-K · filed 2019-03-04 | |||
| 2018-03-31 | $1.55M 10-Q · filed 2019-04-10 | |||
| 2017-12-31 | $5.48M 10-K · filed 2019-03-04 | |||
| 2016-12-31 | $4.68M 10-K · filed 2019-03-04 | |||
| 2015-12-31 | $4.03M 10-K · filed 2018-03-13 | |||
| 2014-12-31 | $2.51M 10-K · filed 2017-03-07 | |||
| 2013-12-31 | $948.00K 10-K · filed 2016-03-08 | |||
| 2012-12-31 | $144.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |